Karyopharm Therapeutics (KPTI) Competitors $6.26 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$6.30 +0.04 (+0.56%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KPTI vs. ACRS, HUMA, AVTE, OGI, TNYA, SOPH, CRGX, RAPT, TIL, and TRDAShould you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include Aclaris Therapeutics (ACRS), Humacyte (HUMA), Aerovate Therapeutics (AVTE), Organigram Global (OGI), Tenaya Therapeutics (TNYA), SOPHiA GENETICS (SOPH), CARGO Therapeutics (CRGX), Rapt Therapeutics (RAPT), Instil Bio (TIL), and Entrada Therapeutics (TRDA). These companies are all part of the "pharmaceutical products" industry. Karyopharm Therapeutics vs. Its Competitors Aclaris Therapeutics Humacyte Aerovate Therapeutics Organigram Global Tenaya Therapeutics SOPHiA GENETICS CARGO Therapeutics Rapt Therapeutics Instil Bio Entrada Therapeutics Karyopharm Therapeutics (NASDAQ:KPTI) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment. Which has more risk and volatility, KPTI or ACRS? Karyopharm Therapeutics has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Does the media refer more to KPTI or ACRS? In the previous week, Karyopharm Therapeutics had 8 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 11 mentions for Karyopharm Therapeutics and 3 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.92 beat Karyopharm Therapeutics' score of 0.72 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Karyopharm Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is KPTI or ACRS more profitable? Karyopharm Therapeutics has a net margin of -90.02% compared to Aclaris Therapeutics' net margin of -802.03%. Karyopharm Therapeutics' return on equity of 0.00% beat Aclaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics-90.02% N/A -84.28% Aclaris Therapeutics -802.03%-34.01%-24.18% Which has preferable valuation & earnings, KPTI or ACRS? Karyopharm Therapeutics has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKaryopharm Therapeutics$145.24M0.37-$76.42M-$14.59-0.43Aclaris Therapeutics$18.72M10.65-$132.07M-$1.37-1.34 Do analysts rate KPTI or ACRS? Karyopharm Therapeutics presently has a consensus target price of $34.00, suggesting a potential upside of 443.13%. Aclaris Therapeutics has a consensus target price of $8.71, suggesting a potential upside of 373.60%. Given Karyopharm Therapeutics' higher possible upside, research analysts clearly believe Karyopharm Therapeutics is more favorable than Aclaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Karyopharm Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Aclaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Do insiders & institutionals hold more shares of KPTI or ACRS? 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 2.8% of Karyopharm Therapeutics shares are owned by company insiders. Comparatively, 5.6% of Aclaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryAclaris Therapeutics beats Karyopharm Therapeutics on 9 of the 17 factors compared between the two stocks. Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPTI vs. The Competition Export to ExcelMetricKaryopharm TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$54.28M$2.55B$5.73B$10.31BDividend YieldN/A60.31%5.90%4.63%P/E Ratio-0.435.4657.1222.76Price / Sales0.37672.77528.74123.58Price / CashN/A169.4937.1760.46Price / Book-0.285.3312.796.29Net Income-$76.42M$32.95M$3.28B$270.51M7 Day Performance-1.11%-0.44%0.22%2.15%1 Month Performance5.74%3.91%4.61%6.35%1 Year Performance-45.48%-3.07%68.33%25.48% Karyopharm Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPTIKaryopharm Therapeutics3.8818 of 5 stars$6.26flat$34.00+443.1%-45.4%$54.28M$145.24M-0.43380ACRSAclaris Therapeutics2.6778 of 5 stars$2.08-1.0%$8.71+319.0%+55.9%$227.50M$18.72M-1.52100Positive NewsGap DownHUMAHumacyte2.8296 of 5 stars$1.41-1.4%$9.75+591.5%-72.9%$226.47M$1.57M-3.13150News CoverageAnalyst ForecastAVTEAerovate TherapeuticsN/A$7.77-0.1%N/A-88.4%$225.21MN/A-2.6020Positive NewsHigh Trading VolumeOGIOrganigram Global1.0923 of 5 stars$1.64-0.6%N/A-8.1%$221.18M$117.47M32.81860TNYATenaya Therapeutics3.1618 of 5 stars$1.40+3.7%$6.25+346.4%-40.0%$220.02MN/A-1.46110Gap UpSOPHSOPHiA GENETICS2.2454 of 5 stars$3.32+2.5%$8.00+141.0%-20.9%$218.96M$65.17M-7.55520CRGXCARGO Therapeutics1.6489 of 5 stars$4.47flat$15.40+244.5%N/A$216.17MN/A-0.96116News CoverageRAPTRapt Therapeutics4.244 of 5 stars$13.28+2.7%$21.57+62.4%+11.7%$213.83M$1.53M-0.9480News CoveragePositive NewsAnalyst UpgradeTILInstil Bio2.8303 of 5 stars$25.77-18.2%$119.00+361.8%-69.5%$212.65MN/A-1.99410High Trading VolumeTRDAEntrada Therapeutics2.5288 of 5 stars$5.28-0.2%$25.67+386.1%-66.3%$201.22M$210.78M-2.97110 Related Companies and Tools Related Companies Aclaris Therapeutics Competitors Humacyte Competitors Aerovate Therapeutics Competitors Organigram Global Competitors Tenaya Therapeutics Competitors SOPHiA GENETICS Competitors CARGO Therapeutics Competitors Rapt Therapeutics Competitors Instil Bio Competitors Entrada Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KPTI) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KPTI Stock Alerts